Prof Zweegman (VU University Medical Center, Amsterdam, Netherlands) and Prof Aapro (Multidisciplinary Oncology Institute, Clinique De Genolier, Switzerland) discuss the latest multiple myeloma data presented at EHA 2014.
Share this Video
Related Videos In Multiple Myeloma
María-Victoria Mateos, EHA 2020: TOURMALINE-MM4 study
Dr María-Victoria Mateos, (Associate Professor of Medicine, Director of Myeloma Unit, University Hospital of Salamanca, Salamanca, Spain) explores unmet needs in the treatment of patients with newly-diagnosed multiple myeloma, and discusses the major findings of the TOURMALINE-MM4 study and the potential of ixazomib in patients no undergoing autologous stem cell transplant. Questions: What are the limitations […]
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]
Patrick Laroche, ASCO20: Bispecific Antibodies in the Treatment of Multiple Myeloma
Patrick Laroche, EMEA Therapeutic Area Leader Hematology at Janssen Pharmaceutica, discusses the benefits of new bispecific antibodies and how he sees the future of multiple myeloma treatment evolving over the coming years. Click here to view Patrick Laroche discussing the potential of CAR-T treatment JNJ-4528 in multiple myeloma Questions 1. Could you tell us more […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!